Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Exenatide, or Byetta, is a synthetic peptide that acts at the receptor for GLP-1 – a hormone that is made in the gastrointestinal track that stimulates insulin secretion and also decreases the ...

Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus.

The Exenatide-PD3 trial randomly assigned 194 Parkinson's patients who were on dopaminergic treatment to either 2 mg of extended-release exenatide by subcutaneous pen injection once weekly (97 ...

To study exenatide's efficacy in reducing hyperglycemia and improving neurologic outcomes, researchers developed the phase 2, international, multicenter, randomized controlled TEXAIS trial.

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...

Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly.

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to ...

Exenatide is not as powerful in eliciting weight loss as the newer drugs, but experts say there is no reason to believe that the more recent drugs would perform differently in studies of brain ...

References: Vijiaratnam N, Girges C, Auld G, et. al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson’s disease in the UK: a phase 3 ...

Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo ...